Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647820 | 0.89 | KMT2A (0.50) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4646816 | 0.87 | KMT2A (0.53) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4643998 | 0.84 | MGLL (0.46) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL11229152 | 0.84 | KMT2A (0.53) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4641736 | 0.82 | KMT2A (0.52) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4642216 | 0.82 | KMT2A (0.52) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4643872 | 0.81 | KMT2A (0.50) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL4642418 | 0.81 | KMT2A (0.60) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL5765022 | 0.81 | SMN1; SMN2 (0.53) | KMT2AMAPTALDH1A1LMNAHTT | |
| SCHEMBL6740542 | 0.81 | KMT2A (0.58) | KMT2AMAPTALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092468-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | US | disclosed |
| US-12234516-B2 | Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-25 | — | — | US | disclosed |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-22 | — | — | US | disclosed |
| EP-3774709-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA | Peloton Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2019191227-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA | PELOTON THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2017053192-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016168510-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016145045-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016145032-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144825-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| CN-100519671-C | Film-forming polymer and antifouling paint | JOTUN AS (NO) | 2009-07-29 | — | — | CN | disclosed |
| EP-1487928-B1 | FILM-FORMING POLYMER AND ANTIFOULING PAINT | JOTUN AS (NO) | 2008-08-13 | — | — | EP | disclosed |
| CN-1643085-A | Film-forming polymer and antifouling paint | JOTUN AS (NO) | 2005-07-20 | — | — | CN | disclosed |
| EP-1487928-A1 | FILM-FORMING POLYMER AND ANTIFOULING PAINT | Jotun AS (NO) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080747-A1 | FILM-FORMING POLYMER AND ANTIFOULING PAINT | JOTUN AS (NO) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | KMT2A 183/4885MAPT 3899/4885ALDH1A1 758/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | KMT2A 186/4885MAPT 3681/4885ALDH1A1 807/4885 |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | KMT2A 532/4885MAPT 4789/4885ALDH1A1 642/4885 |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | HIF1AN, EGLN2, EGLN3 | KMT2A 2368/4885MAPT 4485/4885ALDH1A1 1353/4885 |
| US-12234516-B2 | Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof | HIF1AN, HIF1A, EGLN2 | KMT2A 532/4885MAPT 4789/4885ALDH1A1 642/4885 |
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | KMT2A 510/4885MAPT 3918/4885ALDH1A1 91/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | KMT2A 112/4885MAPT 4155/4885ALDH1A1 676/4885 |
| US-20250092468-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | KMT2A 532/4885MAPT 4789/4885ALDH1A1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.